Evidence map›Paper›PMID 25810396›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

The adaptor 3BP2 is required for KIT receptor expression and human mast cell survival.

Erola Ainsua-Enrich, Eva Serrano-Candelas, Damiana Álvarez-Errico, César Picado, Joan Sayós, Juan Rivera, Margarita Martín

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. KIT as a master regulator of the mast cell lineage.The Journal of allergy and clinical immunology · 2022
    Review
  5. Article
  6. MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis.Journal of immunology (Baltimore, Md. : 1950) · 2021
    Article
  7. Review
  8. Long-Tailed Unconventional Class I Myosins in Health and Disease.International journal of molecular sciences · 2020
    Review
  9. Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
    Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Erola Ainsua-EnrichBiochemistry Unit, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain; Laboratori d'Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain;
Eva Serrano-CandelasBiochemistry Unit, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain; Laboratori d'Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain;
Damiana Álvarez-ErricoBiochemistry Unit, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain; Laboratori d'Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain;
César PicadoLaboratori d'Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain; Networking Research Center on Respiratory Diseases, Institute of Health Carlos III, 28029 Madrid, Spain;
Joan SayósImmunobiology Group, Molecular Biology and Biochemistry Research Center for Nanomedicine, Nanomedicine Program, Vall d'Hebrón Research Institute, Autonomous University of Barcelona, 08035 Barcelona, Spain; Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, Institute of Health Carlos III, 28029 Madrid, Spain; and.
Juan RiveraMolecular Immunology Section, Laboratory of Molecular Immunogenetics, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 20892.
Margarita MartínBiochemistry Unit, Faculty of Medicine, University of Barcelona, 08036 Barcelona, Spain; Laboratori d'Immunoallèrgia Respiratòria Clínica i Experimental, Institut d'Investigacions Biomèdiques August Pi i Sunyer, 08036 Barcelona, Spain; martin_andorra@ub.edu.
Universitat de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USVall d'Hebron Institut de Recerca · ES

Funding

INTRACELLULAR SIGNALING BY THE CELL SURFACE RECEPTOR FOR IGEZ01AR041101 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI RIVERA, JUAN · 1995 to 2008
$2.7M
Molecular Regulation of InflammationZ01AR041155 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI RIVERA, JUAN · 2007 to 2008
$2.0M
Intramural NIH HHS Z01 AR041101Intramural NIH HHS Z01 AR041155
6 · The paper itself

Abstract

SH3-binding protein 2 (3BP2) is a cytoplasmic adaptor protein that acts as a positive regulator in mast cell FcεRI-dependent signaling. The KIT receptor whose ligand is the stem cell factor is necessary for mast cell development, proliferation, and survival as well as for optimal IgE-dependent signal. Activating mutations in KIT have been associated with several diseases including mastocytosis. In the present work, we found that 3BP2 silencing impairs KIT signaling pathways, thus affecting phosphoinositide 3-kinase and MAPK pathways in human mast cells (huMCs) from HMC-1, LAD2 (huMC lines), and CD34(+)-derived mast cells. Unexpectedly, silencing of 3BP2 reduces KIT expression in normal huMCs as well as in HMC-1 cells where KIT is mutated, thus increasing cellular apoptosis and caspase-3/7 activity. 3BP2 silencing reduces KIT transcription expression levels. Interestingly, 3BP2 silencing decreased microphthalmia-associated transcription factor (MITF) expression, a transcription factor involved in KIT expression. Reconstitution of 3BP2 in knockdown cells leads to reversal of KIT expression as well as survival phenotype. Accordingly MITF reconstitution enhances KIT expression levels in 3BP2-silenced cells. Moreover, downregulation of KIT expression by miRNA-221 overexpression or the proteasome inhibitor bortezomib also reduced 3BP2 and MITF expression. Furthermore, KIT tyrosine activity inhibition reduced 3BP2 and MITF expression, demonstrating again a tight and reciprocal relationship between these molecules. Taken together, our results show that 3BP2 regulates huMC survival and participates in KIT-mediated signal transduction by directly controlling KIT receptor expression, suggesting its potential as a therapeutic target in mast cell-mediated inflammatory diseases and deregulated KIT disorders.

Indexed as

Gene Expression RegulationAdaptor Proteins, Signal TransducingApoptosisCaspase 3Caspase 7Cell LineCell SurvivalGene SilencingHumansMast CellsMicrophthalmia-Associated Transcription FactorMutationProto-Oncogene Proteins c-kitRNA, MessengerSignal TransductionTranscription, GeneticAdaptor Proteins, Signal TransducingCaspase 3Caspase 7Microphthalmia-Associated Transcription FactorProto-Oncogene Proteins c-kitRNA, MessengerSH3BP2 protein, human

Identifiers

PMID25810396
PMCPMC4402263
OpenAlexW1635979695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.